| 摘要 |
The invention provides methods of using an FGF-1 protein having at least 80% sequence identity to a human FGF-1 protein to treat metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, type II diabetes, elevated percent body fat, obesity, and fatty liver. Such treatment can be achieved by lowering blood glucose levels, reducing body fat, increasing lean muscle mass, and/or reducing liver steatosis. |
